| アブストラクト | Anti-human epidermal growth factor receptor 2 (HER2) agents have exhibited pronounced tumor-inhibitory activity, yet the accompanying ocular toxicity has frequently been underestimated. We aim to conduct a comprehensive comparative analysis of ocular toxicity risk related to various anti-HER2 agents. We executed a retrospective pharmacovigilance investigation based on the FDA Adverse Event Reporting System (FAERS) database, covering the period from Q2 2018 to Q1 2023. The disproportionality analysis was performed to assess ocular toxicity risk. Multivariate logistic regression was implemented to mitigate potential biases. Moreover, the time to onset of ocular toxicity was also evaluated. A total of 3467 ocular adverse event (AE) reports concerning anti-HER2 agents were collected. At the preferred term (PT) level, there were 69 positive signals, among which excessive eye blinking, abnormal sensation in the eye, and asthenopia presented a significant risk. In comparison to tyrosine kinase inhibitors (TKIs), antibody drugs were associated with a broader range of ocular disorders at Standardized MedDRA Queries (SMQ)levels, including conjunctival disorders, corneal disorders, ocular infections, ocular motility disorders, optic nerve disorders, and retinal disorders. In terms of onset time, pertuzumab displayed an earlier onset at 21.5 days, while trastuzumab deruxtecan had the latest at 91.5 days. In summary, our study reveals varying degrees of ocular toxicity related to anti-HER2 agents, with a significantly higher risk observed in antibody drugs. Additionally, novel ocular toxicity signals, not documented in product labels, have been detected. In the future, further research will be necessary to validate our findings. |
|---|
| ジャーナル名 | International journal of cancer |
|---|
| 投稿日 | 2024/1/13 |
|---|
| 投稿者 | Chen, Heng; Yang, Guoping; Ma, Junlong |
|---|
| 組織名 | Department of Pharmacy, The First Hospital of Changsha, Changsha, Hunan, China.;Center of Clinical Pharmacology, Third Xiangya Hospital, Central South;University, Changsha, Hunan, China.;Hubei Provincial Clinical Research Center for Umbilical Cord Blood Hematopoietic;Stem Cells, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, China. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/38216995/ |
|---|
